.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Uncover prior art in expired and abandoned patents
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Novartis
Chinese Patent Office
Teva
QuintilesIMS
Express Scripts
Moodys
Fuji
Harvard Business School
Farmers Insurance
Boehringer Ingelheim

Generated: June 27, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 091517

« Back to Dashboard
NDA 091517 describes REPAGLINIDE, which is a drug marketed by Actavis Totowa, Standard Chem Pharm, Aurobindo Pharma Ltd, Mylan Pharms Inc, Sandoz Inc, Sun Pharm Inds Inc, Paddock Llc, and Lupin Ltd, and is included in eight NDAs. It is available from thirteen suppliers. Additional details are available on the REPAGLINIDE profile page.

The generic ingredient in REPAGLINIDE is metformin hydrochloride; repaglinide. There are forty-seven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the metformin hydrochloride; repaglinide profile page.

Summary for NDA: 091517

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:1
Therapeutic Class:Blood Glucose Regulators
Formulation / Manufacturing:see details

Pharmacology for NDA: 091517

Mechanism of ActionPotassium Channel Antagonists

Suppliers and Packaging for NDA: 091517

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
REPAGLINIDE
repaglinide
TABLET;ORAL 091517 ANDA Breckenridge Pharmaceutical, Inc. 51991-853 51991-853-01 100 TABLET in 1 BOTTLE (51991-853-01)
REPAGLINIDE
repaglinide
TABLET;ORAL 091517 ANDA Breckenridge Pharmaceutical, Inc. 51991-854 51991-854-01 100 TABLET in 1 BOTTLE (51991-854-01)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength0.5MG
Approval Date:Apr 24, 2015TE:ABRLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength1MG
Approval Date:Apr 24, 2015TE:ABRLD:No

Summary for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength2MG
Approval Date:Apr 24, 2015TE:ABRLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Merck
Deloitte
Covington
Federal Trade Commission
Fuji
Chubb
US Army
Express Scripts
Novartis
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot